It’s the Seizures, S#%&*D! The Tragedy of Recurring Seizures in Adults

Response to First Antiepileptic Drug Trial Predicts Health Outcome in Epilepsy.


PURPOSE: Failure to respond to the initial antiepileptic drug (AED) is a predictor of increased risk of pharmacoresistant epilepsy. Whether response to the first AED also predicts adverse health outcomes is unknown. METHODS: This longitudinal study compared rates of major adverse health outcomes (loss of driving privileges, unemployment, divorce/separation, injury, emergency room admission, hospitalization, and death) in 33 patients who failed the first AED (cases) and 30 patients who became seizure-free with the first AED (controls). Patient data were obtained by chart review and confirmed through a structured interview with each subject at 5–7 years after starting AED treatment. We also assessed between-group differences in quality of life, depression, and adverse AED effects by using standardized instruments completed by each subject at the end of follow-up. KEY FINDINGS: The number of major adverse health outcomes was similarly high during the first year of AED treatment [mean ± standard deviation (SD) 2.64 ± 0.99 for cases and 2.50 ± 1.14 for controls], but thereafter decreased to a greater extent in controls than in cases (p < 0.001). Controls had a higher cumulative probability of experiencing ≥1 year free from major adverse health outcomes compared to cases (p = 0.002). Two cases died during the follow-up, both of sudden unexpected death. Cases had worse quality of life ratings than controls, whereas no significant between-group differences were found for measures of depression and adverse AED effects. In a post hoc analysis limited to cases, patients who became seizure-free with subsequent AED treatments showed for the first 4 years major adverse health outcome rates similar to those recorded in patients with persisting seizures. After 4 years, however, cases who achieved late seizure freedom tended to show a more favorable outcome. SIGNIFICANCE: Patients with epilepsy failing the initial AED trial are at increased risk of experiencing adverse health outcomes, at least for the first 4 years after diagnosis. Incorporating these findings into clinical decision making may aid in reducing delays in surgical referrals for pharmacoresistant epilepsy.

Commentary

The report from Perucca et al. confirms the reality of what we face in the office each day: any seizure occurrence is a major risk for our adult patients. The risk is not the inconvenience of losing 15 to 30 minutes of normal functioning, but is the subtle cumulative risk of a severe social setback such as loss of employment or divorce, and the immediate, impending physical risk of injury, hospitalization, and death. In this study, the authors reviewed the course of a group of carefully selected, high-functioning adults who initiated epilepsy treatment at the Columbia Presbyterian Comprehensive Epilepsy Center. The cohort was divided into two groups: the “controls” (n = 30), those who were seizure-free after the first appropriate antiepileptic drug (AED); and the “cases” (n = 33), those who were not seizure-free. The occurrence of major adverse health outcomes per year for 5 consecutive years after starting treatment was compared between the two groups. Patients were identified through chart review, and then were contacted to participate in the study, which included completing a structured interview and questionnaires. The major adverse health outcomes were loss of driving privileges, unemployment, divorce or separation, injury, emergency room admission, hospitalization, and death. The source of how these events were determined to be major adverse health outcomes is not cited, and they appear to have been derived by the authors. They seem appropriate, however, and interestingly encompass several severe psychosocial stressors.

Notably, the groups were well matched, with 80 to 90 percent of subjects in each group driving and employed at the time of AED initiation; not so after 5 years, especially for the “case” group. (There was no assessment of how many seizures likely occurred before AED treatment in each group. However, if there were more seizures prior to treatment in the “case” group, it would probably not change the eventual implications of this paper, since, to quote Kwan and Brodie: “Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy” [1,1].)

The major epilepsy comorbidities put forth as having as much or more adverse impact on quality of life than seizure
occurrence, such as medication side effects and mood issues, are well accounted for in this study. The Adverse Event Profile (AEP) and the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) are validated assessments for persons with epilepsy, but these scale scores did not differ between groups. And yet, the “cases” were on a generally downhill course, which was reflected in their quality of life scales. Therefore, the increased rates of major adverse health outcomes cannot be attributed to AED adverse effects or depressed mood, but rather to seizures alone.

What therefore, accounts for the relentless occurrence of major adverse events in persons with ongoing seizures, including two deaths in the “cases” but none in the “controls”? Seizures carry physical risks, legal constraints, perceived stigma by the patient, and actual stigmatizing behavior by others. Employers may have a discriminatory attitude toward people who have seizures in the workplace and yet have the responsibility to impose safety-based limitations upon them. These two stances, one clearly morally bad, the other good, become intertwined to the point where one could clearly serve the other. Relationships are strained when illness becomes part of day-to-day concerns, often triggering constant and heightened worry and hyper-vigilance on the part of family members. Not least, the financial stress of chronic illness can be overwhelming. The injuries, emergency room visits, AED trials, anxiety, fear, loss of confidence and self-esteem for the patient, and frayed nerves among family members all contribute to the risks documented in this study. These factors are hard to measure, but the message is that they could be mitigated significantly if the seizures were stopped.

We clearly need to continue to work with our patients, aiming toward seizure-freedom. This study demonstrates that this is the most important thing we can do in order to maximize the quality of life for our epilepsy patients. How can epilepsy doctors and general neurologists improve epilepsy outcomes? We can listen to our patients more carefully, review their studies more vigilantly, think more creatively regarding treatment approaches, and not settle for less than seizure-freedom unless the refractory situation is hitting us over the head. The American Academy of Neurology has put forth eight practice improvement (PI) measures for epilepsy care (2), which include documentation of seizure type, frequency, injuries, medication side effects, and EEG and MRI results and dates on which they were performed. Further, documentation of whether the patient is well-controlled or intractable is required at every visit and consideration for surgical referral is then prompted for refractory patients. For epilepsy doctors, these PI measures seem mundane, and we perform them all the time. However, widely incorporating them into neurology practices could refocus and crystallize the decision pathway for patients who are otherwise continuing to have seizures and for whom, in their partnership with their doctors, there is no existing strategy toward seizure-freedom.

There are many obstacles on the path toward seizure freedom. One is the continuing erosion of reimbursement for sitting and talking with a patient, to discuss treatment options. Procedures are reimbursed, not relationships. However, for epileptologists, one cannot get to the “procedure” without the “relationship.” Another more insidious problem is the perception of a toxic and unethical involvement of physicians with drug and device industries. Fruitful collaborations that could improve the chances of discovering novel compounds to treat epilepsy are currently discouraged by academia, targeted by media, and obstructed by oversight bodies. Further, there is the perception that having seizures once in a while is OK. Healthcare providers may think it is OK, but our patients certainly know that it is not.

by Cynthia L. Harden, MD

References
American Epilepsy Society
Epilepsy Currents Journal
Disclosure of Potential Conflicts of Interest

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
American Epilepsy Society
Epilepsy Currents Journal
Disclosure of Potential Conflicts of Interest

Section #1 Identifying Information

1. Today’s Date: 4/13/2012
2. First Name Cynthia Last Name Harden Degree MD
3. Are you the Main Assigned Author? ☑ Yes ☐ No
   If no, enter your name as co-author:
4. Manuscript/Article Title: Response to first antiepileptic drug trial predicts health outcome in epilepsy
5. Journal Issue you are submitting for: 12.2

Section #2 The Work Under Consideration for Publication
Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
Section #3 Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td></td>
<td></td>
<td>yes</td>
<td>UCB, Glaxo, Lundbeck</td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ No other relationships/conditions/circumstances that present a potential conflict of interest.
☒ Yes, the following relationships/conditions/circumstances are present:

Speaker's Bureau for Glaxo

Thank you for your assistance.

Epilepsy Currents Editorial Board